Seagen; Adcetris; Opdivo; Ipsen; Alladapt Immunotherapeutics; Biogen; Eisai; Bylvay; ADP101; epinephrine; Leqembi

Seagen; Adcetris; Opdivo; Ipsen; Alladapt Immunotherapeutics; Biogen; Eisai; Bylvay; ADP101; epinephrine; Leqembi

Today in FirstWord Pharma 's Industry News newsletter, we cover:

?? Seagen says Adcetris, Opdivo regimen leads to 98% response rate in classical Hodgkin lymphoma

? US clears Bylvay for severe itch due to Alagille syndrome

?? Alladapt looks to advance food allergy drug to Phase III

?? Alzheimer's experts hint at tough sell for Eisai, Biogen's lecanemab in EU

Stay ahead of the curve with access to all the important news and insights in the #Pharma industry with FirstWord Pharma's Industry News newsletter!?Sign up to receive our newsletter and get an in-depth view of today's top stories.

?? https://firstwordpharma.com/register

要查看或添加评论,请登录

FirstWord Pharma的更多文章

社区洞察

其他会员也浏览了